Vitrakvi

Active Ingredient(s): Larotrectinib
FDA Approved: * November 26, 2018
Pharm Company: * LOXO ONCOLOGY INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Vitrakvi Overview

Larotrectinib (tradename Vitrakvi) is a drug for the treatment of cancer.[1] It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. Larotrectinib was initially awarded orphan drug status in 2015 for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.[2] Some clinical trial results were announc...

Read more Vitrakvi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Larotrectinib

Recent Vitrakvi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Larotrectinib
  • Capsule: 100mg, 25mg
  • Solution: 20mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vitrakvi: (3 results)

Sorted by National Drug Code
  • 71777-390 Vitrakvi 25 mg Oral Capsule by Loxo Oncology, Inc.
  • 71777-391 Vitrakvi 100 mg Oral Capsule by Loxo Oncology, Inc.
  • 71777-392 Vitrakvi 20 mg/ml Oral Solution by Loxo Oncology, Inc.

Other drugs which contain Larotrectinib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 22 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA